---
title: "Oramed Pharmaceuticals And Unit Entered Into Joint Venture Agreement With Hefei Tianhui Biotech And Technowl"
description: "Oramed Pharmaceuticals and its unit have entered into a joint venture agreement with Hefei Tianhui Biotech and Technowl Limited. The joint venture aims to initiate a Phase 3 oral insulin trial in the "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/106565668.md"
published_at: "2024-01-23T22:25:01.000Z"
---

# Oramed Pharmaceuticals And Unit Entered Into Joint Venture Agreement With Hefei Tianhui Biotech And Technowl

> Oramed Pharmaceuticals and its unit have entered into a joint venture agreement with Hefei Tianhui Biotech and Technowl Limited. The joint venture aims to initiate a Phase 3 oral insulin trial in the US using Oramed's oral drug delivery technology. Hefei Tianhui Biotech will contribute $70 million in cash to the joint venture, while Oramed will contribute $20 million. The joint venture will focus on developing products based on Oramed's oral insulin and POD™ pipeline.

Jan 23 (Reuters) - Oramed Pharmaceuticals Inc (ORMP.O) :

-   ORAMED PHARMACEUTICALS INC: ON JAN 22, CO AND UNIT ENTERED INTO JOINT VENTURE AGREEMENT WITH HEFEI TIANHUI BIOTECH AND TECHNOWL LIMITED
    
-   ORAMED PHARMACEUTICALS INC - ORAMED AND HTIT WILL INITIALLY HOLD EQUAL SHARES IN JV, WITH EACH OWNING 50% OF EQUITY
    
-   ORAMED PHARMACEUTICALS: PARTIES INTEND FOR JV TO INITIATE PHASE 3 ORAL INSULIN TRIAL IN THE U.S.
    
-   ORAMED PHARMACEUTICALS INC - UNDER JV AGREEMENT, PARTIES WILL ESTABLISH A JOINT VENTURE BASED ON ORAMED’S ORAL DRUG DELIVERY TECHNOLOGY
    
-   ORAMED PHARMACEUTICALS INC - ORAMED WILL BE ENTITLED TO RECEIVE A 3% ROYALTY ON GROSS REVENUES OF JV GENERATED FROM ORAMED RELATED ASSETS
    
-   ORAMED PHARMACEUTICALS INC - UNDER JV, BOARD OF DIRECTORS WILL INITIALLY CONSIST OF EQUAL REPRESENTATION FROM HTIT AND ORAMED
    
-   ORAMED PHARMACEUTICALS INC: HTIT WILL CONTRIBUTE TO JV $70 MILLION IN CASH, WHILE ORAMED WILL CONTRIBUTE $20 MILLION
    
-   ORAMED PHARMACEUTICALS- HTIT TO HAVE OPTION TO INVEST EXTRA FUNDS INTO JV UP TO $20 MILLION, THEREBY INCREASING EQUITY HOLDINGS & BOARD REPRESENTATION
    
-   ORAMED PHARMACEUTICALS: UNDER JV, CO TO TRANSFER INTELLECTUAL PROPERTY RELATED TO ITS ORAL INSULIN & POD TECHNOLOGY, AND OTHER ASSETS IN CO’S PIPELINE
    
-   ORAMED PHARMACEUTICALS- JV TO FOCUS ON DEVELOPMENT OF PRODUCTS BASED ON CO’S ORAL INSULIN AND POD™ PIPELINE & HTIT’S MANUFACTURING CAPABILITIES

### Related Stocks

- [ORMP.US - Oramed Pharma](https://longbridge.com/en/quote/ORMP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Lifeward Secures Up to $47 Million Equity Investment From Oramed for Minority Stake | Lifeward Ltd. has secured a strategic investment from Oramed Pharmaceuticals, allowing Oramed to acquire up to 49.99% eq | [Link](https://longbridge.com/en/news/272415773.md) |
| 07:58 ET
			
			
				Oramed and Lifeward Announce Strategic Transaction | Oramed Pharmaceuticals and Lifeward have announced a strategic transaction involving the transfer of Oramed's oral drug  | [Link](https://longbridge.com/en/news/272414712.md) |
| Cruise operator Carnival to unify dual listing | Carnivalannounced plans to unify its dual listings in New York and London and redomicile to Bermuda. The UK-listed Carni | [Link](https://longbridge.com/en/news/276491689.md) |
| Tempus AI EVP Erik Phelps Sells Shares | Erik Phelps, EVP and Chief Admin. Officer of Tempus AI, sold 9,464 shares of Class A Common Stock on February 19, 2026,  | [Link](https://longbridge.com/en/news/276495655.md) |
| Annette Franqui Purchases 1,540 Shares of OFG Bancorp (NYSE:OFG) Stock | OFG Bancorp Director Annette Franqui purchased 1,540 shares of the company's stock at $42.06 per share, totaling $64,772 | [Link](https://longbridge.com/en/news/276494822.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.